FDA's Sunscreen Data Guidance Lacks Risk/Benefit Balance – Stakeholders

FDA's proposal that sunscreen ingredient sponsors seeking GRASE status conduct maximal usage trials to assess potential for systemic absorption will delay consumer access to new broad-spectrum sunscreens without a sound scientific basis, PASS says in comments on FDA draft guidance. The American Cancer Society and American Academy of Dermatology Association express similar concerns.